NeuroBo Pharmaceuticals shares are trading higher after the company signed an exclusive license agreement providing MThera Pharma Co. with the rights to NB-01.
Portfolio Pulse from Benzinga Newsdesk
NeuroBo Pharmaceuticals shares are trading higher after the company signed an exclusive license agreement providing MThera Pharma Co. with the rights to NB-01.
July 30, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroBo Pharmaceuticals shares are trading higher following the announcement of an exclusive license agreement with MThera Pharma Co. for NB-01.
The exclusive license agreement is a significant development for NeuroBo Pharmaceuticals, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100